Usted buscó: cushing (Maltés - Inglés)

marda ta’ cushing
cushing’s disease

użu fil-marda ta’ cushing
use in cushing’s disease

komuni: sindrome ta’ cushing;
common: cushing’s syndrome;

ipogonadiżmu maskili, sindromu ta ’ cushing, ipotirojdiżmu
the following adverse reactions of moderate to severe intensity with possible or probable relationship to kaletra have been reported.

użu fis-sindrome ta’ cushing indipendenti mill-acth
use in acth-independent cushing’s syndrome

ipogonadiżmu maskili, sindromu cushing (cushing syndrome), ipotirojdiżmu
kaletra does not inhibit cyp2d6, cyp2c9, cyp2c19, cyp2e1, cyp2b6 or cyp1a2 at clinically relevant concentrations (see section 4.3).

Ġew irrappurtati każijiet tas-sindrome ta’ cushing u soppressjoni adrenali.
cases of cushing’s syndrome and adrenal suppression have been reported.

jinkludu s-sindromu ta’ cushing u soppressjoni adrenali f’pazjenti li
yndrome and adrenal suppression have been reported in

sindrome ta’ cushing*, ipertirojdiżmu*, tnixxija mhux adattata tal-ormon antidijuretiku
cushing's syndrome*, hyperthyroidism*, inappropriate antidiuretic hormone secretion

id-doża massima li ntużat għall-kura tas- sindrome ta’ cushing hija 1600 mg/jum.
the maximal dose that was used for treatment of cushing’s syndrome is 1600 mg/day.

signifor jintuża biex jikkura adulti bil-marda ta’ cushing meta l-kirurġija ma tkunx irnexxiet jew ma tkunx għażla.
signifor is used to treat adults with cushing’s disease when surgery has failed or is not an option.

signifor ġie studjat f’165 pazjent adult bil-marda ta’ cushing fejn il-kirurġija ma kinitx adegwata.
signifor was studied in 165 adult patients with cushing’s disease where surgery was not appropriate.

- nuqqas ta ’ funzjoni tat- testikoli, is- sindromu cushing (cushing syndrome) (kundizzjoni
− kaletra tablets can be taken with or without food. − always take kaletra exactly as your doctor has told you. − you should check with your doctor or pharmacist if you are not sure how you should take your medicine.

antaċidi (eż. ranitidine, cimetidine) aminoglutethimide –mediċina użata għall-kura tas-sindromu ta’ cushing
antacids (e.g. ranitidine, cimetidine) aminoglutethimide – a medicine used to treat cushing’s syndrome

is-sindrome ta’ cushing, soppressjoni adrenali, dewmien fit-tkabbir, tnaqqis fid-densità minerali tal-għadam
cushing´s syndrome, adrenal suppression, growth retardation, decrease in bone mineral density

fi studji kliniċi fost pazjenti morda bil-marda ta’ cushing, kien osservat qtcf ta’ >500 msek f’żewġ pazjenti minn 201.
in clinical studies in cushing’s disease patients, qtcf of >500 msec was observed in two out of 201 patients.

fl-assenza ta’ informazzjoni speċifika, l-użu fl-annimali li jbatu mis-sindrome cushing għandu jkun ibbażat fuq il-valutazzjoni ta’ riskju-benefiċċju.
in the absence of specific information, the use in animal suffering from cushing’s syndrome shall be based on the risk-benefit assessment.